Targeted therapies for rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests different targeted treatments for adults with rheumatoid arthritis who have already tried other biologic or targeted medications and need a new option. It aims to find which treatment works best for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been treated with at least one biologic or targeted DMARD for 3 months or more, and it didn't work well enough, or you had to stop due to side effects.
- You cannot have tried more than 2 of these biologic or targeted DMARDs in the past.
- You must be taking a steady, stable dose of methotrexate.
- You must be 18 or older (since arthritis starting before age 17 is excluded).
- You should not have other inflammatory joint diseases besides rheumatoid arthritis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.